This business is for sale — the website, all of its content, the domain and the mobile app. — website, content, domain & app. contact@revisemrcem.com
These are not summaries of ADA, NICE or IDSA — those already exist, and they are better than anything we would write. What these pathways show is where Pakistani practice has to diverge from them, and why: national guideline adaptations, drugs that are not available here, and local resistance data that makes the standard empiric choice the wrong one.
Highest prevalence in the region at 13.8%, and a fifth of moderate-to-severe disease in people who never smoked. Inhaler choice by eosinophil count, biomass smoke advice, admission criteria — and post-TB COPD, where only 27% respond to a bronchodilator against 82% in COPD alone.
Built on: Pakistan Chest Society COPD guideline 2026 (revised) · GOLD 2025
✓ Clinically reviewed Aug 2026
Open →
The national guideline moved to SABA-free treatment — here is the switching table, the ICS dose bands and the exacerbation algorithms. Plus the myths that shape every consultation here, and the guideline's own admission that its central recommendation is an extrapolation.
Built on: Pakistan Chest Society Asthma guideline 2026 · GINA 2025 · BTS/NICE/SIGN NG245
✓ Clinically reviewed Aug 2026
Open →
Magnesium sulphate doses, and the instruction most often missed — give it before she is transferred, not after. Plus the 80 mL/hour fluid limit, the labetalol and hydralazine regimens, the screening method the guideline rules out, and the 40% postnatal eclampsia risk.
Built on: SOGP Hypertensive Disorders in Pregnancy Guidelines 2022 (PAFMJ)
✓ Clinically reviewed Aug 2026
Open →
The regimen with doses and fixed-dose-combination weight bands, the isoniazid-resistant options, monitoring, and the pregnancy, liver, renal and HIV adjustments — plus the three WHO regimens Pakistan declines to use, and where to refer resistant disease.
Built on: Pakistan Chest Society TB guideline 2026 · National Strategic Plan 2024–26 · NTP 2024 paediatric updates
✓ Clinically reviewed Aug 2026
Open →
The world's largest burden, a national programme built for non-specialists, and generic drugs curing 98%. No biopsy needed — includes a working FIB-4 calculator and the rifampicin, PPI and amiodarone interactions.
Built on: National Consensus Practice Guidelines (PSG, PSH, STEP) · PM's Elimination Programme
✓ Clinically reviewed Aug 2026
Open →
Half of Pakistani adults have it and 6% are controlled. The three staged national targets, the CKD-EPI Pak eGFR equation, and the two practices the guideline tells you to stop.
Built on: 4th National Hypertension Guidelines, JPMA 2023 — Pakistan Hypertension League
✓ Clinically reviewed Aug 2026
Open →
Screening starts at 30, not 45. The national guideline does not diagnose on HbA1c. There is no glucagon to prescribe. Includes the RAPID risk score with a working calculator.
Built on: PROMPT (BIDE + Diabetic Association of Pakistan) · GRADE-adolopment of ADA 2021
✓ Clinically reviewed Aug 2026
Open →
The March 2026 national guideline dropped macrolide monotherapy and put doxycycline in its place. The current algorithm, the drug-resistant-pathogen risk factors that branch it, and the fluoroquinolone and tuberculosis trap.
Built on: Pakistan Chest Society — Community Acquired Bacterial Pneumonia, March 2026
✓ Clinically reviewed Aug 2026
Open →
Ciprofloxacin and co-trimoxazole are 24% and 27% susceptible in Pakistan. Which two oral agents still work, why they cannot treat pyelonephritis, and the nitrofurantoin G6PD question.
Built on: Published Pakistani susceptibility series — Islamabad and Dera Ismail Khan
✓ Clinically reviewed Aug 2026
Open →
Each pathway is scoped to the decision local guidance actually changes, not the whole disease. Suggestions for what to cover next are welcome at support@revisefcps1.com.
Looking for a calculator or wizard instead? See our free clinical tools.